Pacific Edge’s American dream

Pacific Edge’s American dream
The US Affordable Care Act can be tricky to navigate. (Image: Getty)
Paul McBeth
Pacific Edge has long wanted to crack the United States market, which it has seen for a long time as validating the hundreds of millions spent in developing its Cxbladder non-invasive cancer detection tool. More than 20 years since listing, after it was spun out of University of Otago research, the company has raised $297.23 million selling shares and convertible preference shares and as people exercised options to fund accumulated losses of $216.8m and counting. That’s not going to change any time soon after the company crashed...

More Markets

NZ sharemarket ends week up nearly 1.2%
Markets Market close

NZ sharemarket ends week up nearly 1.2%

The S&P/NZX 50 Index closed at 12,904.11, up 149.96 points or 1.18%.

Graham Skellern 20 Dec 2024
Marlborough Wine Estates' NZX delisting gets green light
Markets

Marlborough Wine Estates' NZX delisting gets green light

Cost savings were behind the decision to delist, the company says.

John Anthony 20 Dec 2024
Global private equity firm snaps up 50% of Craigs
Markets

Global private equity firm snaps up 50% of Craigs

Partnership with TA Associates tipped to accelerate Craigs' growth.

John Anthony 20 Dec 2024
ComCom delays Manawa takeover deal decision
Markets

ComCom delays Manawa takeover deal decision

Due on Dec 24, the decision will now be in March.

Ian Llewellyn 20 Dec 2024